Glytrin

Glytrin is a prescription medication containing the active ingredient glyceryl trinitrate, supplied as an oromucosal preparation. It belongs to the nitrate vasodilator class and is marketed in the European Union. Glyceryl trinitrate works by releasing nitric oxide, which relaxes blood vessels and reduces the heart’s oxygen demand. Glytrin is used under medical supervision for the treatment and prevention of angina pectoris in patients with chronic stable angina.

Glytrin is indicated for several clinical situations involving myocardial oxygen supply and demand.

- Relief of acute angina pectoris episodes by rapid sublingual administration. - Prevention of angina attacks before physical exertion, emotional stress, or exposure to cold. - Management of chronic stable angina as part of a long‑term regimen, often combined with other anti‑anginal agents. - Use in the emergency setting for rapid alleviation of chest pain when other nitrates are unavailable or contraindicated. - Adjunct therapy in patients undergoing diagnostic cardiac procedures, such as stress testing, that may provoke myocardial ischemia.

Glytrin may cause a range of effects, most of which are related to its vasodilating action.

Common: - Headache, often described as throbbing, due to cerebral vasodilation. - Flushing or warmth in the face and neck. - Dizziness or light‑headedness, especially when standing quickly. - Low blood pressure (hypotension) with possible fainting. - Nausea or vomiting. - Palpitations or feeling of irregular heartbeat.

Serious: - Severe hypotension leading to syncope. - Rapid heart rate (reflex tachycardia) that may be symptomatic. - Allergic reactions such as rash, itching, or swelling of the face and throat. - Methemoglobinemia (rare) causing cyanosis and shortness of breath. - Severe allergic reaction (anaphylaxis) with difficulty breathing, hypotension, and swelling.

When prescribing Glytrin, clinicians consider several precautions to ensure safe use and to minimize adverse outcomes.

- Assess blood pressure before each dose; avoid use in patients with severe hypotension. - Do not combine with phosphodiesterase‑5 inhibitors (e.g., sildenafil) due to risk of profound hypotension. - Use cautiously in patients with recent myocardial infarction or unstable angina. - Monitor for signs of tolerance; dose escalation may be required after prolonged therapy. - Advise patients to sit or lie down when taking the medication to reduce dizziness. - Avoid abrupt discontinuation in patients on long‑term therapy to prevent rebound angina. - Pregnancy and lactation status should be evaluated, as safety data are limited.

Glytrin can interact with several medicines, altering its effect on blood pressure or increasing the risk of adverse reactions.

Avoid: - Concomitant use with phosphodiesterase‑5 inhibitors (e.g., sildenafil, tadalafil) – may cause severe hypotension. - Co‑administration with other nitrates or nitroglycerin preparations – additive vasodilatory effect. - Use with potent vasodilators such as hydralazine – increased risk of low blood pressure. - Concurrent use with alcohol – may exacerbate hypotensive episodes.

Use with caution: - Beta‑blockers – may mask tachycardia, requiring careful monitoring. - Calcium channel blockers (especially dihydropyridines) – can enhance hypotensive effect. - Antihypertensive agents such as ACE inhibitors or ARBs – monitor blood pressure closely. - Loop diuretics – may increase risk of dehydration and orthostatic hypotension.